Kansas City Cancer Center Adopts TomoTherapy® Platform to Advance Patient Care





TomoTherapy Incorporated announced that Kansas City Cancer Center (KCCC) has commenced treating patients with the TomoTherapy® Hi·Art® treatment system, a versatile, CT scanner-based device, that integrates image guidance for increased treatment accuracy and helical radiation therapy delivery for enhanced tumor targeting. KCCC becomes the first TomoTherapy treatment center in Kansas City, and the first US Oncology, Inc., affiliate to adopt TomoTherapy technology in the fight against cancer.

The TomoTherapy Hi·Art system has been installed at KCCC’s new Shawnee Mission location, one of 11 KCCC facilities in the Kansas City area. KCCC is a member of the US Oncology network, which treats more than 650,000 patients a year, or approximately 15 percent of all cancer patients in the U.S.

TomoTherapy treatments began at KCCC-Shawnee Mission in late July. According to Radiation Oncologist James Coster, M.D., many Kansas City area cancer patients have already benefitted from the introduction of this groundbreaking technology. “It’s so precise that radiation can be localized to the cancer itself while nearly eliminating dose to the surrounding healthy tissues,” says Dr. Coster. “It completely changes the way we fight cancers of the head, neck, breast and prostate, and the impact we can make on overall patient health.”

Fred Robertson, M.D., CEO for TomoTherapy Inc., sees the KCCC installation as another key milestone for the company. “TomoTherapy is excited to be working with US Oncology and KCCC. We believe that with TomoTherapy’s advanced, image-guided radiotherapy platform, KCCC will be able to significantly improve patient care.”

About Kansas City Cancer Center and US Oncology, Inc.

Kansas City Cancer Center is a full service cancer healthcare practice, with 11 offices throughout the Kansas City region.  KCCC provides a wide range of patient support, including oncology treatment, diagnostic imaging, genetic risk evaluation and testing and survivorship wellness programs. Its patient-driven mission is to equip individuals and their families with everything they need to battle the disease, manage their care and navigate the insurance issues of a cancer diagnosis – all from a close-to-home environment. For more information on KCCC, please visit www.kccancercenter.com .

Kansas City Cancer Center is united in healing with US Oncology, which supports the nation’s foremost cancer treatment and research network accelerating the availability and use of evidence-based medicine and shared best practices. With more than 1,227 physicians treating more than 650,000 patients at 468 locations, including 95 radiation oncology facilities, throughout 39 states, the US Oncology network and Kansas City Cancer Center provide cancer patients with access to the latest advancements in therapies, clinical research and technology, as well as best-in-class clinical and operational processes that help to advance the quality, safety and cost effectiveness of cancer care. For more information, visit the company’s Web site, www.usoncology.com .

About TomoTherapy Incorporated

TomoTherapy Incorporated has developed, manufactures and sells the TomoTherapy® Hi·Art® treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi·Art treatment system combines integrated CT imaging with radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue, which can lead to improved patient outcomes. The company’s stock is traded on the NASDAQ Global Market under the symbol TOMO.

Investor Contact:

Thomas E. Powell
Chief Financial Officer
608.824.2800
tpowell@tomotherapy.com

Media Contact:
Kevin O’Malley Manager
Corporate Communications
608.824.2800
komalley@tomotherapy.com